Medicinal Cannabis Stigma Declines While Usage Hesitation Remains High
New research indicates that the social stigma surrounding medicinal cannabis is decreasing across New Zealand, according to a survey conducted by Clarity Insight. The survey, commissioned by Cannabis Clinic and released exclusively to media reports, found that 54% of respondents believe medicinal cannabis remains stigmatised. This figure represents a notable decrease from the 65% reported by respondents in the previous year. The survey included 1056 New Zealanders in its comprehensive assessment of public attitudes toward regulated cannabis products.
Despite the reduction in stigma, survey results reveal significant hesitation among the general public regarding personal use of the substance. Specifically, 59% of respondents reported that they have never tried cannabis but would be willing to do so. This willingness level marks a decline from the 78% reported by respondents during the previous year. Furthermore, while 88% of respondents were aware of the existence of medicinal cannabis, only 70% of respondents correctly identified that the substance is legal in New Zealand. This gap between awareness and legal knowledge highlights ongoing public understanding challenges.
Regulatory Framework and Usage
The formal medicinal cannabis scheme commenced operations in 2020. Under this framework, the Medicinal Cannabis Agency has verified over 100 distinct products for use. These verified products include various delivery methods such as vaporisers, oral drops, and items intended for tea preparation. Ministry of Health officials confirmed that the Medicinal Cannabis Agency maintains strict oversight over product verification. However, Ministry of Health officials explicitly stated that the agency does not participate in determining the pricing structure for these medicinal cannabis products.
Current usage statistics indicate that approximately 120,000 people in New Zealand are currently utilizing prescribed medicinal cannabis. Cannabis Clinic chief executive Waseem Alzaher provided context regarding prescription barriers. Waseem Alzaher noted that 27% of respondents expressed uncertainty about whether their general practitioner would prescribe medicinal cannabis to them. This uncertainty reflects broader concerns about medical gatekeeping within the healthcare system. Waseem Alzaher further elaborated that this uncertainty suggests that one in four Kiwis would be unsure that a doctor would prescribe a medicine if they deemed it suitable.
Usage Statistics and Illegal Markets
The survey data also provided insight into the prevalence of cannabis use across the population. Waseem Alzaher stated that there are at least 250,000 to 300,000 Kiwis who currently use cannabis illegally on a regular basis. This figure represents a substantial portion of the population engaging in unregulated cannabis consumption. Additionally, Waseem Alzaher estimated that another 10,000 to 200,000 people would benefit from medicinal cannabis treatments but currently do not use cannabis for any reason. These figures underscore a significant unmet need within the current healthcare landscape for individuals seeking therapeutic cannabis options.
Public Perception and Future Outlook
The findings suggest a complex public perception regarding medicinal cannabis. While the perception of stigma is lessening, the willingness to try the substance remains lower than previous years. The 59% willingness to try the substance represents a shift from the 78% willingness reported last year. These trends suggest that while public attitudes are evolving, significant barriers remain for broader adoption of regulated medicinal cannabis treatments across the country. The ongoing monitoring of these public attitudes will be crucial for future policy development.
Glossary
- Medicinal cannabis — Medicinal cannabis or medical marijuana (MMJ) includes cannabis products and cannabinoid molecules that are prescribed by physicians for their patients. The use of cannabis as medicine has a long history, but has not been as rigorously tested as other medicinal plants due to legal and governmental restrictions, resulting in limited research to define the safety and efficacy of using cannabis to treat diseases.
- vaporisers — The formal medicinal cannabis scheme commenced operations in 2020. Under this framework, the Medicinal Cannabis Agency has verified over 100 distinct products for use. These verified products include various delivery methods such as vaporisers, oral drops, and items intended for tea preparation.
- oral drops — The formal medicinal cannabis scheme commenced operations in 2020. Under this framework, the Medicinal Cannabis Agency has verified over 100 distinct products for use. These verified products include various delivery methods such as vaporisers, oral drops, and items intended for tea preparation.
- Ministry of Health — Ministry of Health officials confirmed that the Medicinal Cannabis Agency maintains strict oversight over product verification. However, Ministry of Health officials explicitly stated that the agency does not participate in determining the pricing structure for these medicinal cannabis products.
- general practitioner — Waseem Alzaher noted that 27% of respondents expressed uncertainty about whether their general practitioner would prescribe medicinal cannabis to them. This uncertainty reflects broader concerns about medical gatekeeping within the healthcare system.
This article was written with AI assistance from multiple news reports and is reviewed by our editors under our editorial principles. Editorial Standards · Tips & Contact
Comments 0